These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18479495)

  • 21. Toward a role for statins in immunomodulation.
    Mach F
    Mol Interv; 2002 Dec; 2(8):478-80. PubMed ID: 14993398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes.
    Simon TG; Butt AA
    World J Gastroenterol; 2015 Jul; 21(27):8293-303. PubMed ID: 26217081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C.
    Ikeda M; Kawai Y; Mori K; Yano M; Abe K; Nishimura G; Dansako H; Ariumi Y; Wakita T; Yamamoto K; Kato N
    Liver Int; 2011 Jul; 31(6):871-80. PubMed ID: 21645219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluvastatin inhibits hepatitis C replication in humans.
    Bader T; Fazili J; Madhoun M; Aston C; Hughes D; Rizvi S; Seres K; Hasan M
    Am J Gastroenterol; 2008 Jun; 103(6):1383-9. PubMed ID: 18410471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication.
    Kim SS; Peng LF; Lin W; Choe WH; Sakamoto N; Kato N; Ikeda M; Schreiber SL; Chung RT
    Gastroenterology; 2007 Jan; 132(1):311-20. PubMed ID: 17241881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Selvapatt N; Habibi MS; Brown A
    J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statins can exert dual, concentration dependent effects on HCV entry in vitro.
    Blanchet M; Le QT; Seidah NG; Labonté P
    Antiviral Res; 2016 Apr; 128():43-8. PubMed ID: 26868875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matrix conditions and KLF2-dependent induction of heme oxygenase-1 modulate inhibition of HCV replication by fluvastatin.
    Wuestenberg A; Kah J; Singethan K; Sirma H; Keller AD; Rosal SR; Schrader J; Loscher C; Volz T; Bartenschlager R; Lohmann V; Protzer U; Dandri M; Lohse AW; Tiegs G; Sass G
    PLoS One; 2014; 9(5):e96533. PubMed ID: 24801208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
    Iqbal S; Yousuf MH; Yousaf MI
    World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.
    Zoulim F; Moreno C; Lee SS; Buggisch P; Horban A; Lawitz E; Corbett C; Lenz O; Fevery B; Verbinnen T; Shukla U; Jessner W
    Virol J; 2018 Jan; 15(1):26. PubMed ID: 29378602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
    Sultanik P; Mallet V; Lagaye S; Casrouge A; Dorival C; Barthe Y; Fontaine H; Hézode C; Mottez E; Bronowicki JP; Carrat F; Theodorou I; Abel L; Gayat E; Fontanet A; Pol S; Albert ML;
    Liver Int; 2015 Jul; 35(7):1833-44. PubMed ID: 25556540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis.
    Zheng YX; Zhou PC; Zhou RR; Fan XG
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):759-766. PubMed ID: 28240613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism.
    Ali N; Allam H; Bader T; May R; Basalingappa KM; Berry WL; Chandrakesan P; Qu D; Weygant N; Bronze MS; Umar S; Janknecht R; Sureban SM; Huycke M; Houchen CW
    PLoS One; 2013; 8(11):e80304. PubMed ID: 24260365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
    Zeuzem S; Nelson DR; Marcellin P
    Antivir Ther; 2008; 13(6):747-60. PubMed ID: 18839776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.
    Shirakawa H; Matsumoto A; Joshita S; Komatsu M; Tanaka N; Umemura T; Ichijo T; Yoshizawa K; Kiyosawa K; Tanaka E;
    Hepatology; 2008 Dec; 48(6):1753-60. PubMed ID: 18925643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model.
    Umehara T; Sudoh M; Yasui F; Matsuda C; Hayashi Y; Chayama K; Kohara M
    Biochem Biophys Res Commun; 2006 Jul; 346(1):67-73. PubMed ID: 16750511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of chronic hepatitis C.
    Bihl F; Negro F
    Minerva Med; 2009 Dec; 100(6):459-65. PubMed ID: 20010481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
    Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.